A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
Inclusion Criteria:
Exclusion Criteria:
Fullerton, California 92835, United States
Los Angeles, California 90095, United States
Porto Alegre, Rio Grande do Sul 90035-003, Brazil
Corbeil-Essonnes, Cedex 91106, France
Frankfurt am Main, 60528, Germany
Homburg, 66421, Germany
Merdia, Yucatán 97133, Mexico
Elblag, 82-300, Poland
Grodzisk Mazowiecki, 05-825, Poland
Petrozavodsk, Karelia Republic 185019, Russia
Kazan', Republic of Tatarstan, Russia 420103, Russia
Moscow, 119049, Russia
Novosibirsk, 630099, Russia
Goodmayes, Essex IG3 8YB, United Kingdom
Romford, Essex RM7 0AG, United Kingdom